Prostate Cancer

PSA Surveillance Every 2 Years after Surgery for Low-risk Prostate Cancer?
Prostate-specific antigen (PSA) measurements at 2 years should capture the majority of low-risk cases that progress after treatment with radical prostatectomy, suggests a new study in the September issue of the Journal of Urology.
 
No Significant Difference Found from Deferred Radical Prostatectomy
For men with localized low-risk prostate cancer, there is no rush to decide on a treatment option, according to the National Prostate Cancer Register (NPCR) of Sweden Follow-up Study published online in the Journal of Urology. This suggestion is based on findings that after median follow-up of 8 years, men who underwent prompt radical prostatectomy had no significant difference in the presence of one of three adverse pathology features or in prostate cancer–specific mortality than men who deferred surgery for up to 19 months.
 
3D-EBRT for Prostate Cancer May Increase Risk of Hip Fracture

SAN FRANCISCO—Prostate cancer patients undergoing three-dimensional external beam radiation therapy (3DEBRT) for prostate cancer may be at an increased risk of hip fracture and could benefit from additional measures to improve bone health following treatment, according to a study by Minneapolis researchers.

Long-term ADT May Increase Risk for Colorectal Cancer
Men treated with long-term androgen deprivation therapy (ADT) for prostate cancer are at increased risk for colorectal cancer, according to a study released in the Journal of the National Cancer Institute.